Z/E 4-HYDROXY TAMOXIFEN
Ductal Breast Carcinoma In Situ
Northwestern UniversitySmall moleculePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the Ductal Breast Carcinoma In Situ cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ROPIVACAINE Zealand University Hospital | Phase 4 | BB |
SUFENTANYL Zealand University Hospital | Phase 4 | BB |
TAMOXIFEN Northwestern University | Phase 3 | BB |
Arimidex Alliance for Clinical Trials in Oncology | Phase 3 | BB |
TAMOXIFEN National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Z/E 4-HYDROXY TAMOXIFEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →